{
  "meta": {
    "title": "Contraception",
    "url": "https://brainandscalpel.vercel.app/contraception-210cb589.html",
    "scrapedAt": "2025-11-30T11:13:55.655Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Are more lipid-friendly</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Decrease the risk of venous thromboembolism</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase the risk of breakthrough bleeding</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Are not used for emergency contraception</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Third-generation oral contraceptive pills containing norgestimate and gestodene, along with estrogens:</span></p>",
      "unique_key": "DT1191109",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191109,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Third-generation oral contraceptive pills (OCPs)</strong> contain <strong>newer progestins</strong> like <strong>norgestimate</strong>, <strong>gestodene</strong>, and <strong>desogestrel</strong>, combined with ethinyl estradiol (an estrogen). These formulations were developed to improve metabolic profiles and reduce androgenic side effects compared to earlier generations.</p>\r\n<p>Third-generation progestins have <strong>minimal androgenic activity</strong>.</p>\r\n<p>They have a <strong>better effect on lipid metabolism</strong>:</p>\r\n<ul>\r\n<li><strong>Increase HDL (good cholesterol)</strong></li>\r\n<li><strong>Lower LDL (bad cholesterol)</strong></li>\r\n<li>Minimal impact on triglycerides.</li>\r\n</ul>\r\n<p>Hence, they are considered <strong>more lipid-friendly</strong> compared to second-generation progestins (like levonorgestrel).</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509047b64139d-5829-4628-8bf2-7445f747b09f.png\"><p><strong>Explanation of incorrect options: </strong></p>\r\n<p><strong>Decrease the risk of thromboembolism (Option B):<br /> </strong>Third-generation OCPs <strong>do not decrease the risk of venous thromboembolism (VTE)</strong>. They have been associated with a <strong>higher risk of VTE</strong> compared to second-generation pills (e.g., those containing levonorgestrel). This is due to their <strong>stronger estrogenic effects on hepatic coagulation factors</strong>, leading to increased clotting risk.</p>\r\n<p><strong>Increase the risk of breakthrough bleeding (Option C):<br /> </strong>Third-generation pills typically offer <strong>better cycle control</strong> and are less androgenic, which tends to <strong>reduce</strong> rather than increase the incidence of <strong>breakthrough bleeding</strong>. Breakthrough bleeding is more common with <strong>low-dose or irregular use</strong> of OCPs, not specifically due to third-generation progestins.</p>\r\n<p><strong>Are not used for emergency contraception (Option D):<br /> </strong>While they are <strong>not the first choice</strong>, some combined oral contraceptives-including those with third-generation progestins-<strong>can be used for emergency contraception</strong> using the <strong>Yuzpe method</strong> (multiple pills taken at specific intervals). However, dedicated emergency contraception pills like levonorgestrel-only or ulipristal are preferred.</p>",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Preventing ovulation</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibiting implantation</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Bringing about alterations in cervical mucus</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The progesterone component of OCP acts by:</span></p>",
      "unique_key": "DT1191111",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191111,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Actions of the progesterone component of combined oral contraceptives:</p>\r\n<ul>\r\n<li>Suppresses <strong>ovulation</strong> by its inhibitory action on the pituitary and the hypothalamus. This is predominantly achieved by estrogens but even by progesterone.</li>\r\n<li>Causes atrophic changes in the<strong> endometrium</strong> and prevents nidation even if fertilization occurs.</li>\r\n<li>Acts on the<strong> cervical mucus, </strong>making it thick and tenacious and impenetrable by sperms.</li>\r\n</ul>\r\n<p>The third-generation progestogens have a higher affinity for progesterone receptor and have a role in inhibiting ovulation. The main function of progestogens in combined pills is to counteract the undesirable effects of estrogen such as endometrial hyperplasia and heavy withdrawal bleeding.</p>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Mala N</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Triquilar</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Femilon</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Novelon</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 21-year-old woman with a history of migraine with aura seeks contraception. She is advised to avoid high-dose estrogen formulations. Which of the following combined oral contraceptive pills contains the lowest dose of estrogen and would be the most appropriate choice in her case?</span></p>",
      "unique_key": "DT1191115",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191115,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>In women with migraine with aura, <strong>estrogen-containing contraceptives</strong> can <strong>increase the risk of stroke</strong>, especially at higher estrogen doses. Hence, <strong>low-estrogen dose formulations</strong> are preferred, or even progestin-only methods if risks are high.</p>\r\n<p><strong>Femilon</strong> contains <strong>only 20 &micro;g of ethinylestradiol</strong>, making it the lowest estrogen dose among the options.</p>\r\n<p>It is therefore the <strong>safest among the combined OCPs listed</strong> for a woman with migraine with aura <strong>if</strong> a combined pill is to be used.</p><p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240402a1f21d4a-fe70-4c2d-9e2a-f86eea9e22c4.jpg\"></p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Mala N (Option A):<br /> </strong>Contains <strong>30 &micro;g</strong> estrogen - higher than Femilon.</p>\r\n<p><strong>Triquilar (Option B):<br /> </strong>A triphasic pill with <strong>varying doses</strong> of estrogen, reaching up to <strong>40 &micro;g</strong>, which is <strong>not suitable</strong> in migraine with aura.</p>\r\n<p><strong>Novelon (Option D):<br /> </strong>Also contains <strong>30 &micro;g</strong> estrogen, making it a <strong>higher dose</strong> compared to Femilon.</p>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Salpingitis</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Hepatic adenoma</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Ovary CA</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Fibroadenosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Oral contraceptive pills decrease the incidence of all of the following conditions except:</span></p>",
      "unique_key": "DT1191117",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191117,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>OCPs <em>increase</em> the risk of hepatic adenomas</strong>, especially with long-term use.</p>\r\n<p>Hepatic adenomas are benign liver tumors that can rupture and cause bleeding, and their incidence is higher in women on OCPs.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509048d6d1fa1-8c95-4c5a-8b23-2175fca1ac6a.png\"><p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Salpingitis (Option A):<br /> </strong>OCPs thicken cervical mucus, reducing the ascent of pathogens &rarr; <strong>decreased risk of pelvic inflammatory disease (PID)</strong>and salpingitis.</p>\r\n<p><strong>Ovary cancer (Option C):<br /> </strong>OCPs <strong>suppress ovulation</strong>, reducing the number of times the ovarian epithelium is disrupted. This is protective against <strong>ovarian cancer</strong>.</p>\r\n<p><strong>Fibroadenosis (Option D):<br /> </strong>Also known as <strong>fibrocystic breast disease</strong>, which can be hormone-sensitive. OCPs <strong>stabilize hormonal fluctuations</strong>, often <strong>reducing symptoms and incidence</strong> of fibroadenosis.</p>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Breast</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Liver</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Cervix</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Ovarian</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">OCP gives protection against following cancers:</span></p>",
      "unique_key": "DT1191120",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191120,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Combined oral contraceptive pills (<strong>OCPs</strong>) provide <strong>strong protection against ovarian cancer</strong>. This protective effect:</p>\r\n<ul>\r\n<li><strong>Increases with duration of OCP use</strong> (significant after 5+ years).</li>\r\n<li>Is thought to result from <strong>suppression of ovulation</strong>, reducing repeated trauma and repair of the ovarian epithelium, which is implicated in carcinogenesis.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509045c8d6048-0961-4e1e-9950-a5b55839f371.png\"><p><strong>Explanation of Incorrect options: </strong></p>\r\n<p><strong>Breast (Option A):<br /> OCPs may slightly increase the risk</strong> of breast cancer, especially in current or recent users.</p>\r\n<ul>\r\n<li>Risk returns to baseline after discontinuation.</li>\r\n<li>Controversial and varies with age, duration, and family history.</li>\r\n</ul>\r\n<p><strong>Liver (Option B):<br /> OCPs increase the risk</strong> of <strong>benign hepatic adenomas</strong>, and there is no protective effect against <strong>hepatocellular carcinoma</strong>. In fact, in regions with hepatitis B or aflatoxin exposure, estrogens may even worsen hepatic tumorigenesis.</p>\r\n<p><strong>Cervix (Option C):<br /> </strong>Long-term OCP use has been linked to an <strong>increased risk of cervical cancer</strong>, especially with coexisting <strong>HPV infection</strong>.</p>\r\n<ul>\r\n<li>OCPs may not cause cancer directly but can <strong>facilitate persistence of HPV</strong> and changes in cervical epithelium.</li>\r\n</ul>",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased risk of ovarian tumour</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased risk of endometrial cancer</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased risk of liver adenoma</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased risk of fibroadenoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">OCP's intake causes all except:</span></p>",
      "unique_key": "DT1191123",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191123,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Fibroadenoma</strong> is a <strong>benign breast tumor</strong> influenced by hormonal levels, but <strong>OCPs do not increase the risk</strong> of fibroadenoma. OCPs may <strong>stabilize hormonal fluctuations</strong>, leading to <strong>decreased cyclic breast changes</strong> (like fibroadenosis), though their effect on true fibroadenomas is generally <strong>neutral or slightly protective</strong>.</p>\r\n<p><strong>Side effects of OCPs are:</strong></p>\r\n<p><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240402f8d84f90-7c2d-47e6-8559-84e167ef9c74.jpg\" alt=\"\" /></p>\r\n<p><strong>Explanation of Incorrect options: </strong></p>\r\n<p><strong>Decreased risk of ovarian tumour (Option A):<br /> </strong>This is a well-established benefit of OCP use. By suppressing ovulation, OCPs reduce the number of times the ovarian epithelium is disrupted, which lowers the risk of epithelial ovarian cancer. Protection increases with longer duration of use and persists even after discontinuation.</p>\r\n<p><strong>Decreased risk of endometrial cancer (Option B):<br /> </strong>The progestin component of OCPs counters the proliferative effects of estrogen on the endometrium, thus preventing hyperplasia and significantly reducing the risk of endometrial carcinoma. This protective effect can last for years after stopping OCPs.</p>\r\n<p><strong>Increased risk of liver adenoma (Option C):<br /> </strong>Estrogen-containing OCPs, especially with prolonged use, are associated with an increased risk of hepatic adenomas. These are benign liver tumors that can rupture or, in rare cases, transform malignantly. This is a known adverse effect of long-term OCP use.</p>",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Bacterial vaginosis</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Chlamydial endocervicitis</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Vaginal warts</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Genital herpes</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The use of combined OCPs is associated with an increased incidence of:</span></p>",
      "unique_key": "DT1191124",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191124,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The use of <strong>combined oral contraceptive pills (OCPs)</strong> has been associated with an <strong>increased risk of Chlamydia trachomatis infections</strong>, particularly <strong>chlamydial endocervicitis</strong>. This occurs due to hormonal changes caused by OCPs, which can:</p>\r\n<ul>\r\n<li>Cause <strong>ectopy (cervical eversion)</strong>, exposing the columnar epithelium of the endocervix. This epithelium is more susceptible to <strong>Chlamydia</strong>.</li>\r\n<li>Alter the <strong>cervical mucus</strong>, making it more penetrable to certain pathogens like Chlamydia (though it becomes less penetrable to others like gonococcus).</li>\r\n<li>Reduce local immune responses slightly, facilitating ascending infection.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect options: </strong></p>\r\n<p><strong>Bacterial vaginosis (Option A):<br /> </strong>OCPs are generally associated with a <strong>reduced risk</strong> of bacterial vaginosis. Estrogen stabilizes the vaginal flora and promotes lactobacilli dominance, lowering vaginal pH and inhibiting overgrowth of anaerobes.</p>\r\n<p><strong>Vaginal warts (Option C):<br /> </strong>Caused by <strong>HPV infection</strong>, which is sexually transmitted. OCPs may be associated with <strong>persistent HPV infection</strong>over long durations, but there is <strong>no clear evidence</strong> they increase the incidence of <strong>genital warts</strong> specifically. Condom use and vaccination are more directly protective.</p>\r\n<p><strong>Genital herpes (Option D):<br /> </strong>Herpes simplex virus (HSV) transmission is primarily influenced by <strong>sexual activity and contact with active lesions</strong>, not OCP use. OCPs do <strong>not increase the incidence</strong> of genital herpes.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<p><strong>Infections and Oral contraception:</strong></p>\r\n<p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240402db18730c-5d09-4b2e-8e31-e0f67b671c85.jpg\"></p>\r\n<p><strong>Note:</strong></p>\r\n<ul>\r\n<li>If question says PID and does not specify any organism-Then OCP'S overall not only decrease the incidence of PID but also risk of hospitalisation and severity of the disease is decreased.</li>\r\n<li>For protection against PID, at least 12 months of continuous use is necessary and this protection is limited only to current users.</li>\r\n</ul>",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute intermittent porphyria</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Systemic lupus</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Thrombosis</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Anemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 22-year-old woman presents to the emergency department with severe abdominal pain, nausea, and vomiting. She also reports recent episodes of anxiety, irritability, and hallucinations. She has no fever or tenderness on abdominal examination. She started taking combined oral contraceptive pills 2 weeks ago. Urine collected during the episode turns dark on standing. What is the diagnosis ?</span></p>",
      "unique_key": "DT1191128",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191128,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This patient presents with <strong>classic features of Acute Intermittent Porphyria (AIP)</strong>, a rare metabolic disorder involving a defect in <strong>porphobilinogen deaminase</strong>, leading to accumulation of <strong>porphyrin precursors</strong>.</p>\r\n<p>Combined oral contraceptive pills contain <strong>estrogen</strong> and <strong>progestin</strong>, and <strong>estrogen</strong> is a well-known <strong>trigger</strong> for acute porphyric attacks.</p>\r\n<h4><strong>Mechanism:</strong></h4>\r\n<ul>\r\n<li>ALA synthase is the <strong>rate-limiting enzyme</strong> in the heme biosynthesis pathway.</li>\r\n<li>Estrogens <strong>increase hepatic ALA synthase activity</strong>, especially in genetically predisposed individuals (those with AIP).</li>\r\n<li>This leads to <strong>increased production of ALA and PBG</strong>, which cannot be further metabolized due to enzyme deficiency (PBG deaminase), leading to <strong>accumulation</strong>.</li>\r\n</ul>\r\n<p>OCPs, especially due to their estrogen content, can <strong>precipitate acute attacks of AIP</strong> by <strong>stimulating heme synthesis</strong>, which leads to the accumulation of toxic intermediates in patients with the enzyme deficiency.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904211e9c1c-177e-4e32-a3eb-b3c15ef73a23.png\">",
      "correct_choice_id": 71,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Gossypol</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">DMPA</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Testosterone enanthate</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Cyproterone acetate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Hypokalemic paralysis is a side effect of:</span></p>",
      "unique_key": "DT1191131",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191131,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Gossypol</strong> is a <strong>polyphenolic compound</strong> derived from cottonseed, previously studied as a <strong>male contraceptive</strong> due to its <strong>spermatotoxic effects</strong>. However, its use has been <strong>limited or abandoned</strong> due to significant <strong>toxicity</strong>.<strong><br /> </strong>Gossypol can cause <strong>loss of intracellular potassium</strong>, leading to <strong>hypokalemia</strong>, which manifests as <strong>flaccid paralysis</strong>, especially of proximal muscles.</p>\r\n<ul>\r\n<li>Mechanism: Impaired Na<sup>+</sup>/K<sup>+</sup> ATPase function and mitochondrial toxicity</li>\r\n<li>Can be severe and potentially life-threatening if not corrected</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect options: </strong></p>\r\n<p><strong>DMPA (Depot medroxyprogesterone acetate) (Option B):<br /> </strong>This is a long-acting injectable <strong>progestin contraceptive</strong> used in females. Common side effects include <strong>weight gain, menstrual irregularities, delayed return to fertility, and decreased bone density</strong>. It is <strong>not associated with hypokalemia</strong> or paralysis.</p>\r\n<p><strong>Testosterone enanthate (Option C):<br /> </strong>An <strong>androgen</strong> used for male hypogonadism or anabolic purposes. Side effects include <strong>polycythemia, acne, gynecomastia, and cardiovascular risks</strong>, but <strong>not hypokalemic paralysis</strong>.</p>\r\n<p><strong>Cyproterone acetate (Option D):<br /> </strong>An <strong>anti-androgen</strong> used in conditions like prostate cancer and hirsutism. It can cause <strong>hepatotoxicity, fatigue, and decreased libido</strong>, but <strong>not hypokalemia or paralysis</strong>.</p>",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Oviductal motility</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Uterine endometrium</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Cervix</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibiting ovulation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Newer progestational contraceptives primarily act by:</span></p>",
      "unique_key": "DT1191133",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191133,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Newer progestational contraceptives</strong> (such as desogestrel, drospirenone, and norgestimate) are designed to have <strong>high progestational activity</strong> with minimal androgenic or estrogenic effects. Their <strong>primary mechanism of action</strong> is:</p>\r\n<ul>\r\n<li><strong>Inhibition of ovulation<br /> </strong>This occurs via <strong>suppression of the mid-cycle luteinizing hormone (LH) surge</strong>, which prevents the release of the ovum from the ovary.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509046b32103b-491e-4b1f-a3aa-fa402032fadd.png\"><p><strong>Explanation of Incorrect options:</strong></p>\r\n<p><strong>Cervical mucus thickening</strong> <strong>(Option C):<br /> </strong>Makes it more difficult for sperm to penetrate, but this is a <strong>secondary effect</strong>.</p>\r\n<p><strong>Endometrial atrophy</strong> <strong>(Option B):<br /> </strong>Renders the uterine lining unreceptive to implantation - again, a <strong>supportive but not primary</strong> mechanism.</p>\r\n<p><strong>Alteration of oviductal motility (Option A):<br /> </strong>Progestins may affect tubal motility, but this effect is <strong>minimal and not central</strong> to their contraceptive action.</p>",
      "correct_choice_id": 94,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Irregular vaginal bleeding may be a side effect</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Used in with combination with oral contraceptive pills</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Cannot be used in lactation</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Prevents ectopic pregnancy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">True statement about Minipill is:</span></p>",
      "unique_key": "DT1191134",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191134,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The <strong>minipill</strong> is a <strong>progestin-only oral contraceptive</strong>. It contains <strong>no estrogen</strong>, making it suitable for women who cannot or should not take estrogen (e.g., lactating mothers, smokers over 35, those with migraine with aura).</p>\r\n<h4><strong>Side Effects:</strong></h4>\r\n<ul>\r\n<li><strong>Irregular vaginal bleeding</strong> or <strong>spotting</strong> is the <strong>most common side effect</strong> of the minipill.</li>\r\n<li>This occurs due to <strong>unstable endometrial lining</strong> from continuous progestin exposure without the stabilizing effect of estrogen</li>\r\n</ul>\r\n<p><strong>Explanation of incorrect options:</strong></p>\r\n<p><strong>Used in combination with oral contraceptive pills (Option B):<br /> </strong>This is incorrect. The minipill <strong>is itself a type of oral contraceptive</strong>. It is <strong>not used in combination</strong> with combined oral contraceptives (which contain both estrogen and progestin). Using both would be redundant and potentially increase side effects without added benefit.</p>\r\n<p><strong>Cannot be used in lactation (Option C):<br /> </strong>Incorrect. The <strong>minipill is the preferred contraceptive during lactation</strong>. Estrogen can reduce milk supply, but <strong>progestin-only pills do not affect breastfeeding</strong> and are safe during this period.</p>\r\n<p><strong>Prevents ectopic pregnancy (Option D):<br /> </strong>Incorrect. While the minipill reduces the overall risk of pregnancy, <strong>if pregnancy occurs</strong>, the risk of it being <strong>ectopic is higher</strong> compared to pregnancies on combined pills. This is because progestin slows <strong>tubal motility</strong>, allowing for possible implantation in the fallopian tube.</p>",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Irregular bleeding</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Thromboembolism</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Hirsutism</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Weight gain</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old woman presents to your clinic with complaints of irregular menstrual bleeding for the past few weeks. She mentions that she was recently prescribed norethisterone for menstrual irregularities. On further questioning, she denies any major medical illnesses and is not on any other medications. What is the most likely side effect she is experiencing due to norethisterone?</span></p>",
      "unique_key": "DT1191135",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191135,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Norethisterone</strong> is a <strong>synthetic progestin</strong> commonly used for:</p>\r\n<ul>\r\n<li>Menstrual disorders</li>\r\n<li>Hormonal contraception (as part of combined OCPs or as a progestin-only pill)</li>\r\n<li>Endometriosis and abnormal uterine bleeding</li>\r\n</ul>\r\n<p>In <strong>progestin-only formulations</strong>, especially at <strong>low doses</strong> (like in the minipill), <strong>irregular bleeding or spotting</strong> is the most frequent and characteristic side effect.</p>\r\n<h4><strong>Mechanism: </strong></h4>\r\n<ul>\r\n<li>Continuous progestin without cyclic estrogen leads to <strong>endometrial instability</strong>.</li>\r\n<li>The endometrial lining becomes thin and fragile, resulting in <strong>unscheduled or breakthrough bleeding</strong>.</li>\r\n</ul>\r\n<p><strong>Explanation of incorrect options:</strong></p>\r\n<p><strong>Thromboembolism (Option B):<br /> </strong>Progestins <strong>alone</strong> (like norethisterone) have <strong>minimal thromboembolic risk</strong>. The risk is much higher with <strong>estrogen-containing pills</strong>, especially those with ethinyl estradiol.</p>\r\n<p><strong>Hirsutism (Option C):<br /> </strong>While some older progestins (e.g., levonorgestrel) have mild <strong>androgenic activity</strong>, <strong>norethisterone</strong> is <strong>less likely</strong> to cause clinically significant hirsutism. It is not the characteristic problem.</p>\r\n<p><strong>Weight gain (Option D):<br /> </strong>Though often reported anecdotally, <strong>controlled studies have not consistently shown significant weight gain</strong> due to progestins like norethisterone. It's not a defining side effect.<br /> </p>",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Menorrhagia</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Metrorrhagia</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Polymenorrhea</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Amenorrhea</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In a woman on a subdermal progesterone implant, the menstrual abnormality seen is :</span></p>",
      "unique_key": "DT1191136",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191136,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Subdermal progesterone implants</strong> (such as <strong>etonogestrel implants</strong>, e.g., Implanon or Nexplanon) are <strong>long-acting progestin-only contraceptives</strong> that release a low, continuous dose of hormone.</p>\r\n<p>The most common menstrual abnormality seen in subdermal progesterone implant is Metorraghia.</p>\r\n<ul>\r\n<li><strong>Metrorrhagia</strong> - irregular, unpredictable <strong>intermenstrual bleeding</strong> or <strong>spotting</strong></li>\r\n<li>This is due to <strong>unstable endometrial development</strong> under continuous low-level progestin stimulation, which leads to <strong>irregular shedding</strong></li>\r\n<li>Progestin <strong>suppresses ovulation</strong> and <strong>thins the endometrial lining</strong>, but:</li>\r\n<li>Without cyclical estrogen support, the endometrium becomes <strong>atrophic and fragile</strong></li>\r\n<li>This results in <strong>irregular shedding</strong>, leading to <strong>frequent, light, and unpredictable bleeding episodes</strong></li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect options: </strong></p>\r\n<p><strong>Menorrhagia (Option A):<br /> </strong>Heavy, prolonged bleeding is <strong>not typical</strong> with progestin implants. In fact, endometrial thinning usually leads to <strong>lighter bleeding</strong> or even amenorrhea over time.</p>\r\n<p><strong>Polymenorrhea (Option C):<br /> </strong>Refers to <strong>frequent regular cycles (&lt;21 days apart)</strong>. This is not the typical bleeding pattern seen with implants, which cause <strong>irregular, not regular</strong>, bleeding.</p>\r\n<p><strong>Amenorrhea (Option D):<br /> </strong>Can occur, especially <strong>after prolonged use</strong>, as the endometrium becomes very thin. However, <strong>metrorrhagia</strong> is <strong>more common</strong>, especially in the <strong>first 6-12 months</strong> of use.</p>",
      "correct_choice_id": 122,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">There is increased incidence of menorrhagia</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">This system can be used as hormone replacement therapy</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">This method is useful for the treatment of endome- trial hyperplasia</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Irregular uterine bleeding can be a problem initially</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements is incorrect regarding levonorgestrel releasing intrauterine contraceptive devices:</span></p>",
      "unique_key": "DT1191137",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191137,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>LNG containing IUCDs <strong>do not cause menorrhagia</strong>, rather are used for management of menorrhagia as they decrease blood loss.</p>\r\n<p><strong>Levonorgestrel-releasing intrauterine contraceptive devices (LNG-IUDs)</strong> - such as <strong>Mirena</strong> - are long-acting reversible contraceptives that release <strong>progestin locally</strong> into the uterus.</p>\r\n<h4><strong>Effect on Menstruation:</strong></h4>\r\n<ul>\r\n<li>LNG-IUDs cause <strong>endometrial atrophy</strong>, which leads to:\r\n<ul>\r\n<li><strong>Reduced menstrual blood loss</strong></li>\r\n<li><strong>Improvement in menorrhagia</strong></li>\r\n<li>In some cases, <strong>amenorrhea</strong> with long-term use</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>This system can be used as hormone replacement therapy (Option B):<br /> Correct.</strong> In postmenopausal women receiving systemic estrogen, a levonorgestrel-releasing IUD can be used to <strong>protect the endometrium</strong> from unopposed estrogen stimulation. This <strong>reduces the risk of endometrial hyperplasia</strong> during hormone replacement therapy (HRT).</p>\r\n<p><strong>This method is useful for the treatment of endometrial hyperplasia (Option C):<br /> Correct.</strong> The local progestin effect of the LNG-IUD makes it effective in <strong>reversing simple endometrial hyperplasia without atypia</strong>, and it's being increasingly used as a <strong>non-surgical option</strong> in selected patients.</p>\r\n<p><strong>Irregular uterine bleeding can be a problem initially (Option D):<br /> Correct.</strong> During the first few months of use, <strong>irregular spotting or bleeding</strong> is common due to <strong>endometrial remodeling</strong>. This typically resolves over time as the endometrium becomes more uniformly atrophic.</p>",
      "correct_choice_id": 131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduced retrograde menstruation</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased ovulation</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Thickened cervical mucus</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Decidual changes in the endometrium</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All of the following mechanisms might account for a reduce-risk of upper genital tract infection in users of progestin-releasing IUDs, except:</span></p>",
      "unique_key": "DT1191138",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191138,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Progestin-releasing intrauterine devices (IUDs)</strong> (e.g., levonorgestrel IUDs like <strong>Mirena</strong>) lower the risk of <strong>pelvic inflammatory disease (PID)</strong> and upper genital tract infections through <strong>local hormonal effects</strong>, not systemic suppression of ovulation.</p>\r\n<p><strong>Progestin-releasing IUDs </strong>do not consistently<strong> suppress ovulation</strong>. Unlike systemic progestins in oral contraceptives, the hormone in LNG-IUDs acts primarily <strong>locally in the uterus</strong>, and ovulation <strong>continues normally in most users</strong>. Therefore, this mechanism <strong>does not contribute</strong> to the reduction in upper genital tract infection risk.</p>\r\n<p><strong>Explanation of Incorrect options:</strong></p>\r\n<p><strong>Reduced retrograde menstruation (Option A):<br /> Correct.</strong> LNG-IUDs reduce the volume of menstrual bleeding, thereby <strong>limiting retrograde menstruation</strong>, which may play a role in spreading infection into the upper genital tract.</p>\r\n<p><strong>Thickened cervical mucus (Option C):<br /> Correct.</strong> Progestins <strong>thicken cervical mucus</strong>, making it <strong>less permeable to sperm and pathogens</strong>, which serves as a <strong>mechanical barrier</strong> to ascending infections.</p>\r\n<p><strong>Decidual changes in the endometrium (Option D):<br /> Correct.</strong> The endometrium becomes <strong>decidualized and atrophic</strong>, creating an <strong>unfavorable environment</strong> for bacterial growth and <strong>reducing pathogen adherence and invasion</strong>.</p>",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Has born at least one child</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Is willing to check IUD tail</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Has a history of ectopic pregnancy</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Has normal menstrual periods</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old woman visits the family planning clinic seeking a long-term, non-hormonal contraceptive method. She has regular menstrual cycles and one living child. She expresses willingness to follow up and monitor for any complications. On further history, she reports a previous ectopic pregnancy managed medically.</span></p>",
      "unique_key": "DT1191140",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191140,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Copper-T (Cu-T)</strong> is a <strong>non-hormonal intrauterine contraceptive device (IUCD)</strong> that works primarily by:</p>\r\n<ul>\r\n<li>Creating a <strong>local inflammatory reaction toxic to sperm and ova</strong></li>\r\n<li>Preventing <strong>fertilization</strong> and, to a lesser extent, implantation</li>\r\n</ul>\r\n<p>A woman with a <strong>prior ectopic pregnancy</strong> is <strong>not an ideal candidate</strong> for Cu-T insertion. Women with a <strong>prior ectopic pregnancy</strong> are at <strong>higher baseline risk</strong> of having another ectopic pregnancy in the future due to preexisting <strong>tubal damage or scarring and </strong>iImpaired <strong>tubal motility</strong></p>\r\n<p>Although <strong>IUDs reduce the </strong>overall risk of pregnancy, if pregnancy does occur, the IUD provides <strong>less protection against ectopic implantation</strong> compared to intrauterine implantation. If pregnancy happens with an IUD in situ, the <strong>proportion of ectopic pregnancies is significantly higher</strong>.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904b8c60726-e37e-46f7-8e21-97e508373f75.png\"><p><strong>Explanation of Incorrect options:</strong></p>\r\n<p><strong>Has borne at least one child (Option A):<br /> Correct.</strong> Parous women (those who have delivered at least one child) are generally <strong>good candidates</strong> for Cu-T insertion due to:</p>\r\n<ul>\r\n<li>Easier insertion</li>\r\n<li>Better uterine size suitability</li>\r\n<li>Possibly reduced risk of expulsion and pain</li>\r\n</ul>\r\n<p><strong>Is willing to check IUD tail (Option B):<br /> Correct.</strong> Regular self-checking of IUD threads ensures proper placement and helps in <strong>early detection of expulsion or displacement</strong>. Patient cooperation is essential for effective use.</p>\r\n<p><strong>Has normal menstrual periods (Option D):<br /> Correct.</strong> Women with normal (i.e., not heavy or painful) periods tolerate Cu-T better, since Cu-T can sometimes cause <strong>increased menstrual bleeding and cramping</strong>.</p>",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">CuT380A</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">CuT200</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Nova T</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Multiload</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old multiparous woman visits the family planning clinic seeking a long-term, reversible contraceptive method. She expresses a preference for an intrauterine contraceptive device (IUCD) and specifically asks for one that protects for up to 10 years. Which of the following IUCDs would be most appropriate for her?</span></p>",
      "unique_key": "DT1191142",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191142,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>CuT380A</strong> is a <strong>copper-releasing intrauterine contraceptive device (IUCD)</strong> that has the <strong>longest approved duration of use</strong> among the commonly used copper IUDs.</p>\r\n<ul>\r\n<li><strong>Design:</strong> T-shaped plastic frame wound with <strong>380 mm<sup>2</sup> of copper wire</strong></li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090465b2dfde-5ca9-404c-ba69-1d19899ca1ca.png\"><ul>\r\n<li><strong>Duration of action:</strong> <strong>10 years</strong></li>\r\n<li><strong>Efficacy:</strong> Failure rate is <strong>less than 1%</strong></li>\r\n<li><strong>Mechanism:</strong> Copper induces a <strong>local sterile inflammatory reaction</strong> that is toxic to sperm and ova, preventing fertilization</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect options: </strong></p>\r\n<p><strong>CuT200 (Option B):<br /> </strong>Contains <strong>200 mm<sup>2</sup> of copper</strong>, with a <strong>lifespan of 3 years</strong>. It is <strong>less effective</strong> and used less frequently today.</p>\r\n<p><strong>Nova T (Option C):<br /> </strong>A <strong>T-shaped IUD</strong> with <strong>200-300 mm<sup>2</sup> of copper and silver core</strong>, effective for about <strong>5 years</strong>.</p>\r\n<p><strong>Multiload (Option D):<br /> </strong>Available in <strong>Cu250 and Cu375</strong> forms:</p>\r\n<ul>\r\n<li><strong>Multiload Cu250:</strong> 3 years</li>\r\n<li><strong>Multiload Cu375:</strong> <strong>5 years</strong></li>\r\n</ul>\r\n",
      "correct_choice_id": 161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Leave the IUD in place without any other treatment</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Remove the IUD to decrease the risk of malformations</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Remove the IUD to decrease the risk of infection</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Terminate the pregnancy because of the high risk of malformations.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An intrauterine pregnancy of approximately 10 weeks gestation is confirmed in a 30 year old, gravida 5, para 4 woman with an IUD in place. The patient expresses a strong desire for the pregnancy to be continued. On examination, the string of the IUD is noted to be protruding from the cervical os. The most appropriate course of action is to:</span></p>",
      "unique_key": "DT1191143",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191143,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>In cases where <strong>pregnancy occurs with an intrauterine device (IUD) in situ</strong>, there are <strong>increased risks</strong> for both <strong>maternal and fetal complications</strong>, especially:</p>\r\n<ul>\r\n<li><strong>Septic miscarriage</strong></li>\r\n<li><strong>Second-trimester spontaneous abortion</strong></li>\r\n<li><strong>Preterm labor</strong></li>\r\n<li><strong>Chorioamnionitis</strong></li>\r\n</ul>\r\n<p>Therefore, <strong>if the IUD strings are visible</strong>, and <strong>the patient desires to continue the pregnancy</strong>, the <strong>IUD should be removed</strong> to reduce the risk of <strong>ascending infection and pregnancy loss</strong>.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Leave the IUD in place without any other treatment (Option A):<br /> Incorrect.</strong> Leaving the IUD in situ increases the risk of:</p>\r\n<ul>\r\n<li><strong>Miscarriage</strong></li>\r\n<li><strong>Septic abortion</strong></li>\r\n<li><strong>Preterm delivery<br /> </strong>Removal is recommended <strong>when strings are accessible</strong> and <strong>removal is feasible without disrupting the pregnancy</strong>.</li>\r\n</ul>\r\n<p><strong>Remove the IUD to decrease the risk of malformations (Option B):<br /> Incorrect reasoning.</strong> The presence of an IUD <strong>does not increase the risk of congenital malformations</strong>. The main concern is <strong>infection and pregnancy loss</strong>, not teratogenicity.</p>\r\n<p><strong>Terminate the pregnancy because of the high risk of malformations (Option D):<br /> Incorrect.</strong> As above, <strong>IUDs are not associated with fetal malformations</strong>. Termination is <strong>not indicated</strong> solely because of the presence of an IUD, especially when the patient wants to continue the pregnancy.<br /> </p>",
      "correct_choice_id": 173,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Hysteroscopy</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">No need of removal (wait and watch)</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">IUD hook</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Laparoscopy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old P1L1 had Cu T inserted 2 years back. On examination Cu T threads are not seen. USG shows Cu T partly in the abdominal cavity. Method of removal is:</span></p>",
      "unique_key": "DT1191144",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191144,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>When an intrauterine device (IUD) is found <strong>partly or fully outside the uterine cavity</strong>, especially <strong>within the abdominal cavity</strong>, <strong>it must be removed</strong> due to risk of:</p>\r\n<ul>\r\n<li>Bowel injury</li>\r\n<li>Adhesions</li>\r\n<li>Peritonitis</li>\r\n</ul>\r\n<p>In such cases, <strong>laparoscopy</strong> is the <strong>preferred method</strong> as it allows direct visualization and safe retrieval of the migrated IUD.</p>\r\n<p><strong>Explanation of Incorrect options:</strong></p>\r\n<p><strong>Hysteroscopy (Option A):<br /> </strong>Used when the IUD is still <strong>within the uterine cavity</strong>, especially when threads are not seen but the device is confirmed to be intrauterine.<br /> <strong>Not suitable</strong> if the IUD is outside the uterus.</p>\r\n<p><strong>No need of removal (Option B):<br /> </strong>A <strong>displaced or migrated IUD</strong> must be removed. Leaving it in the peritoneal cavity poses risks of peritonitis.</p>\r\n<p><strong>IUD hook (Option C):<br /> </strong>These are used when threads are not visible but the IUD is still <strong>within the uterine cavity</strong>.<br /> <strong>Not appropriate</strong> when the IUD has migrated outside the uterus.</p>",
      "correct_choice_id": 184,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Undiagnosed vaginal bleeding</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetes</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Smoking</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Obesity</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old woman, G3P2, presents to the family planning clinic requesting long-term contraception. She is morbidly obese with a BMI of 40. She has a history of menorrhagia, and her last delivery was 6 weeks ago. She is currently exclusively breastfeeding and is diabetic.She also mentions that she smokes a pack of cigarettes per day for the last six years. Which of the following is an absolute contraindication to IUCD insertion in this patient?</span></p>",
      "unique_key": "DT1191145",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191145,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\r\n<p>Undiagnosed vaginal bleeding is an <strong>absolute contraindication</strong> to IUCD insertion. Any abnormal, unexplained uterine bleeding must first be investigated to rule out serious pathology such as <strong>endometrial hyperplasia, malignancy, or pregnancy</strong>. Inserting an IUCD in this scenario may delay diagnosis, worsen bleeding, and expose the patient to additional risk if underlying conditions are missed. Management of such patients must include a proper diagnostic workup before any contraceptive device is inserted.</p>\r\n<p>The other factors-<strong>diabetes, smoking, and obesity-</strong>are not contraindications, and IUCDs are often preferred in such clinical profiles.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904993e8756-8a06-4196-a33c-0484c515caa5.png\"><h3><strong>Explanation of Incorrect Options:</strong></h3>\r\n<p><strong>Diabetes (Option B):<br /> </strong>Diabetes, including insulin-dependent diabetes, is <strong>not a contraindication</strong> to IUCD use. Both copper IUCDs and hormonal IUS (like levonorgestrel-releasing systems) are considered safe. In fact, these methods are often preferred in diabetic women due to their non-systemic hormonal profile and minimal metabolic impact.</p>\r\n<p><strong>Smoking (Option C):<br /> </strong>Smoking is a major concern with <strong>estrogen-containing contraceptives</strong>, particularly in women over 35 due to increased risk of cardiovascular events. However, IUCDs do not contain estrogen and are <strong>safe for smokers</strong> of any age.</p>\r\n<p><strong>Obesity (Option D):<br /> </strong>Obesity is also <strong>not a contraindication</strong>. IUCD efficacy is not influenced by body weight, and the method is safe. In fact, IUCDs are preferred in obese women because combined hormonal contraceptives carry increased thromboembolic risks in this population.</p>",
      "correct_choice_id": 191,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">Delaying/inhibiting ovulation</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibiting fertilization</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">Preventing implantation of the fertilized egg</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">Interrupting an early pregnancy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Emergency contraception prevents pregnancy by all of the following mechanisms, except:</span></p>",
      "unique_key": "DT1191146",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191146,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Emergency contraception refers to methods used to <strong>prevent pregnancy after unprotected sexual intercourse</strong> or contraceptive failure. The commonly used methods include:</p>\r\n<ul>\r\n<li><strong>Levonorgestrel (LNG) pills</strong></li>\r\n<li><strong>Ulipristal acetate</strong></li>\r\n<li><strong>Combined estrogen-progestin pills (Yuzpe regimen)</strong></li>\r\n<li><strong>Copper intrauterine device (Cu-IUD)</strong></li>\r\n</ul>\r\n<p>Emergency contraception does not <strong>terminate or interrupt an established pregnancy</strong>.</p>\r\n<ul>\r\n<li>According to the World Health Organization (WHO) and medical consensus, <strong>pregnancy begins at implantation</strong>, not fertilization.</li>\r\n<li>EC works <strong>before implantation</strong>, and thus <strong>does not cause abortion</strong>.</li>\r\n<li>If implantation has already occurred, emergency contraceptives are <strong>ineffective</strong> and should not be used.</li>\r\n<li>Therefore, <strong>EC is not an abortifacient</strong>.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904de1f5ac3-1f96-4558-8c0f-2db3e03bc6bb.png\"><p><strong>Explanation of Incorrect options:</strong></p>\r\n<p><strong>Delaying/inhibiting ovulation (Option A):<br /> </strong>This is a <strong>primary mechanism</strong> of EC pills like <strong>levonorgestrel</strong> and <strong>ulipristal acetate</strong>. They inhibit or delay the release of the ovum, especially if taken before ovulation.</p>\r\n<p><strong>Inhibiting fertilization (Option B):<br /> </strong>Certain methods, especially <strong>ulipristal</strong> and <strong>copper IUCDs</strong>, can impair sperm function or the transport of the ovum, <strong>reducing the chances of fertilization</strong>.</p>\r\n<p><strong>Preventing implantation of the fertilized egg (Option C):<br /> </strong>The <strong>copper IUCD</strong> can alter the endometrial lining, making it hostile to implantation. This is one of the mechanisms when Cu-IUD is used as emergency contraception.<br /> However, this does <strong>not interrupt an existing pregnancy</strong>; it only prevents it from being established.</p>",
      "correct_choice_id": 204,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">OCP</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">Danazol</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Levonorgestrel</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">Mifepristone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 24-year-old woman presents to the outpatient clinic requesting emergency contraception after unprotected sexual intercourse 36 hours ago. She has regular menstrual cycles and no significant medical history. She is not currently using any form of contraception and does not desire pregnancy at this time. Which of the following is the emergency contraceptive of choice for her?</span></p>",
      "unique_key": "DT1191147",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191147,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The emergency contraceptive pill of choice for her would be Levonorgestrel. This is the <strong>emergency contraceptive of choice</strong> in most clinical situations.</p>\r\n<ul>\r\n<li>It is a <strong>progestin-only</strong> pill, typically given as <strong>5 mg single dose</strong> or <strong>0.75 mg twice 12 hours apart</strong>.</li>\r\n<li>It is <strong>most effective within 72 hours</strong>, but can be used up to 120 hours (though efficacy declines with time).</li>\r\n<li>It acts primarily by <strong>inhibiting or delaying ovulation</strong>.</li>\r\n<li>It has <strong>few side effects</strong>, is <strong>readily available</strong>, and is <strong>widely recommended by WHO and national guidelines</strong>.</li>\r\n</ul>\r\n<p><strong>Drugs used for Emergency contraception</strong></p>\r\n<p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240402b01fcf56-42b9-4416-a1d5-1c14897af0c3.jpg\"></p>\r\n<p><strong>Explanation of incorrect options: </strong></p>\r\n<p><strong>OCP (Option A):</strong></p>\r\n<p>Combined estrogen-progestin pills (Yuzpe regimen) were historically used for emergency contraception.</p>\r\n<ul>\r\n<li>However, they are <strong>less effective</strong> and have <strong>more side effects</strong> (e.g., nausea, vomiting) than levonorgestrel.</li>\r\n<li>Not first choice anymore.</li>\r\n</ul>\r\n<p><strong>Danazol (Option B):</strong></p>\r\n<p>Danazol is an <strong>androgenic agent</strong> used for conditions like <strong>endometriosis</strong> or <strong>fibrocystic breast disease</strong>. It has <strong>no role</strong> in emergency contraception.</p>\r\n<p><strong>Mifepristone (Option D):</strong></p>\r\n<p>Mifepristone is an <strong>antiprogestin</strong> that can be used for emergency contraception, especially at <strong>low doses (10 mg)</strong>.</p>\r\n<ul>\r\n<li>However, its primary use is for <strong>medical abortion</strong> at higher doses (200 mg), often combined with misoprostol.</li>\r\n<li>Due to <strong>availability issues</strong>, <strong>regulatory restrictions</strong>, and <strong>delayed action</strong>, it is <strong>not considered the first-line choice</strong>in emergency contraception.</li>\r\n</ul>",
      "correct_choice_id": 213,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">24 hours</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">48 hours</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">72 hours</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">120 hours</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Emergency contraceptives are effective if administered within the following period after unprotected intercourse:</span></p>",
      "unique_key": "DT1191148",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191148,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Emergency contraception is <strong>effective up to 120 hours (5 days)</strong> after unprotected intercourse. However, <strong>earlier administration is more effective</strong>, regardless of the method used. The maximum time limits for various methods are as follows:</p>\r\n<ul>\r\n<li><strong>Levonorgestrel pills:</strong>\r\n<ul>\r\n<li>Most effective within <strong>72 hours</strong>,</li>\r\n<li>Can be used up to <strong>120 hours</strong>, though efficacy declines with time.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Ulipristal acetate (30 mg):</strong>\r\n<ul>\r\n<li>Effective up to <strong>120 hours</strong></li>\r\n<li>Slightly more effective than levonorgestrel, especially between 72-120 hours.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Copper IUCD:</strong>\r\n<ul>\r\n<li><strong>Most effective</strong> form of EC</li>\r\n<li>Can be inserted up to <strong>120 hours</strong> after unprotected sex</li>\r\n<li>Also provides <strong>ongoing contraception</strong>.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<h3><strong>Explanation of Incorrect Options:</strong></h3>\r\n<p><strong>24 hours (Option A):<br /> </strong>Levonorgestrel is <strong>very effective</strong> when taken within 24 hours, but this is <strong>not the outer limit</strong> of its use. So this is incorrect for a \"maximum window\" question.</p>\r\n<p><strong>48 hours (Option B):<br /> </strong>Similar to Option A, it's within the effective window, but not the maximum.</p>\r\n<p><strong>72 hours (Option C):<br /> </strong>This is the <strong>traditional upper limit</strong> for <strong>levonorgestrel-only</strong> pills, but newer data and broader EC options (like ulipristal and Cu-IUD) extend this limit to <strong>120 hours</strong>, making Option D the correct choice.</p>",
      "correct_choice_id": 224,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">Electrocoagulation</span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">Vasectomy</span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">Clipping</span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">Medroxy progesterone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Permanent sterilization is all except?</span></p>",
      "unique_key": "DT1191149",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191149,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This is <strong>not</strong> a method of permanent sterilization.</p>\r\n<ul>\r\n<li>It is a <strong>long-acting, reversible hormonal contraceptive</strong>, administered as an <strong>intramuscular injection every 3 months</strong> (Depot Medroxyprogesterone Acetate or DMPA).</li>\r\n<li>It works by <strong>inhibiting ovulation</strong>, thickening cervical mucus, and altering the endometrium.</li>\r\n<li><strong>Fertility returns</strong> after discontinuation, although it may take several months.<br /> Thus, it is a <strong>temporary contraceptive</strong>, not a sterilization method.</li>\r\n</ul>\r\n<h3><strong>Explanation of Incorrect Options </strong></h3>\r\n<h3><strong>Electrocoagulation (Option A):</strong></h3>\r\n<ul>\r\n<li>A method of <strong>female sterilization</strong> where the fallopian tubes are <strong>sealed using an electrical current</strong>.</li>\r\n<li>It causes tubal blockage via thermal injury and scarring.</li>\r\n</ul>\r\n<p><strong>Vasectomy (Option B):</strong></p>\r\n<ul>\r\n<li>A method of <strong>male sterilization</strong>, involving surgical <strong>ligation or excision of the vas deferens</strong>.</li>\r\n<li>It prevents sperm from entering the ejaculate and is considered <strong>permanent</strong>, though reversal is sometimes possible.</li>\r\n</ul>\r\n<p><strong>Clipping (Option C):</strong></p>\r\n<ul>\r\n<li>A <strong>mechanical method of tubal ligation</strong> in females, where a <strong>clip (e.g., Filshie or Hulka clip)</strong> is applied to occlude the fallopian tubes.</li>\r\n<li>It is minimally invasive and commonly used in laparoscopic sterilization.</li>\r\n</ul>",
      "correct_choice_id": 234,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 25,
      "choices": [
        {
          "id": 241,
          "text": "<p><span style=\"font-size:12.0pt;\">Pomeroy's tubal ligation</span></p>"
        },
        {
          "id": 242,
          "text": "<p><span style=\"font-size:12.0pt;\">Irwing's technique</span></p>"
        },
        {
          "id": 243,
          "text": "<p><span style=\"font-size:12.0pt;\">Laparoscopic tubal ligation with silastic bands</span></p>"
        },
        {
          "id": 244,
          "text": "<p><span style=\"font-size:12.0pt;\">Laparoscopic tubal ligation with clips</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Sterilization procedure with maximum chances of reversal is:</span></p>",
      "unique_key": "DT1191150",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191150,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Laparoscopic tubal ligation with clips </strong>offers the <strong>highest chance of successful reversal</strong> among all sterilization techniques.</p>\n<ul>\n<li><strong>Clips</strong> (e.g., <strong>Filshie clips</strong> or <strong>Hulka clips</strong>) are applied across a <strong>small segment of the fallopian tube</strong>, causing minimal tissue damage.</li>\n<li>Because <strong>less of the tube is destroyed or removed</strong>, the <strong>anatomical and functional integrity</strong> of the tube is more easily restored during reversal surgery (tuboplasty).</li>\n<li>Reversal success rates can reach <strong>up to 75-80%</strong>, depending on the remaining healthy tubal length and patient factors.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904d1c3d72d-9c3f-446f-9cc7-7a630507c64b.png\"><p><strong>Explanation of Incorrect Options:</strong></p>\n<p><strong>Pomeroy's tubal ligation (Option A):</strong></p>\n<ul>\n<li>A widely used method involving <strong>ligation and excision of a loop</strong> of the fallopian tube.</li>\n<li>While technically reversible, it removes a <strong>larger segment</strong> of the tube, making reversal more complex and success rates lower.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090490aded76-5981-4b85-ba76-ec3944a3f956.png\"><p><strong>Irwing's technique (Option B):</strong></p>\n<ul>\n<li>A method involving <strong>partial salpingectomy</strong> (removal of part of the fallopian tube), which is <strong>not easily reversible</strong> due to significant tissue loss.</li>\n</ul>\n<p><strong>Laparoscopic tubal ligation with silastic bands (Option C):</strong></p>\n<ul>\n<li>Involves placing a <strong>silastic ring</strong> around a loop of the fallopian tube, which leads to <strong>necrosis of a larger tubal segment</strong>.</li>\n<li>Reversibility is <strong>less favorable</strong> than with clips due to more extensive tissue damage.</li>\n</ul>",
      "correct_choice_id": 244,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 26,
      "choices": [
        {
          "id": 251,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral pills</span></p>"
        },
        {
          "id": 252,
          "text": "<p><span style=\"font-size:12.0pt;\">Norplant</span></p>"
        },
        {
          "id": 253,
          "text": "<p><span style=\"font-size:12.0pt;\">IUCD</span></p>"
        },
        {
          "id": 254,
          "text": "<p><span style=\"font-size:12.0pt;\">Condom</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Best mode of contraception for a newly married lady with rheumatic heart disease:</span></p>",
      "unique_key": "DT1191151",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191151,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Condoms are the <strong>safest and most appropriate initial contraceptive choice</strong> for a newly married woman with rheumatic heart disease.</p>\r\n<ul>\r\n<li>They are <strong>non-hormonal</strong>, <strong>non-invasive</strong>, and <strong>free from systemic side effects</strong>.</li>\r\n<li>They do <strong>not increase thromboembolic risk</strong>, which is a concern in some cardiac patients.</li>\r\n<li>They are also <strong>readily available</strong> and <strong>reversible</strong>.</li>\r\n<li>For a newly married couple not yet planning pregnancy, <strong>barrier methods</strong> offer acceptable efficacy with minimal risk.</li>\r\n</ul>\r\n<h3><strong>Explanation of Incorrect Options:</strong></h3>\r\n<p><strong>Oral pills (Option A):</strong></p>\r\n<ul>\r\n<li>Combined oral contraceptives contain <strong>estrogen</strong>, which can <strong>increase thromboembolic risk</strong>-a major concern in <strong>cardiac patients</strong>, especially those with valvular heart disease or atrial fibrillation.</li>\r\n<li>Thus, <strong>not preferred</strong> in rheumatic heart disease.</li>\r\n</ul>\r\n<p><strong>Norplant (Option B):</strong></p>\r\n<ul>\r\n<li>A long-acting <strong>progestin-only implant</strong>, which may be safer than estrogen-containing methods.</li>\r\n<li>However, it is <strong>not first-line in newly married women</strong> and <strong>requires minor surgery</strong>, which may not be suitable in all cardiac patients.</li>\r\n<li>Also, <strong>irregular bleeding</strong> may be a side effect.</li>\r\n</ul>\r\n<p><strong>IUCD (Option C):</strong></p>\r\n<ul>\r\n<li>Intrauterine devices, especially copper IUCDs, can cause <strong>menorrhagia</strong>, which may be problematic in women with <strong>valvular disease and anemia</strong>.</li>\r\n<li>Also, there is a theoretical <strong>risk of endocarditis</strong> from ascending infection, particularly in patients with <strong>valvular lesions</strong>.</li>\r\n</ul>",
      "correct_choice_id": 254,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 27,
      "choices": [
        {
          "id": 261,
          "text": "<p><span style=\"font-size:12.0pt;\">Barrier method</span></p>"
        },
        {
          "id": 262,
          "text": "<p><span style=\"font-size:12.0pt;\">Combined OCP</span></p>"
        },
        {
          "id": 263,
          "text": "<p><span style=\"font-size:12.0pt;\">Lactational amenorrhoea</span></p>"
        },
        {
          "id": 264,
          "text": "<p><span style=\"font-size:12.0pt;\">Progesterone-only pill</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The Ideal contraceptive for a lactating mother is:</span></p>",
      "unique_key": "DT1191152",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191152,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The <strong>ideal contraceptive</strong> for a <strong>lactating mother</strong> is the <strong>progesterone-only pill</strong>, also known as the <strong>mini-pill</strong>.</p>\r\n<ul>\r\n<li>It is <strong>safe during breastfeeding</strong>, as it does <strong>not suppress milk production</strong>, unlike estrogen-containing pills.</li>\r\n<li>POPs are effective, reversible, and can be <strong>started anytime after delivery</strong>, especially <strong>after 6 weeks</strong> postpartum in fully breastfeeding women.</li>\r\n<li>They work by <strong>thickening cervical mucus</strong>, <strong>inhibiting ovulation</strong>, and making the <strong>endometrium unsuitable for implantation</strong>.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090497384c4d-1b31-4571-8e2e-fd54f6cfbadc.png\"><h3><strong>Explanation of Incorrect Options:</strong></h3>\r\n<p><strong>Barrier method (Option A):</strong></p>\r\n<ul>\r\n<li><strong>Safe and non-hormonal</strong>, but <strong>less effective</strong> than hormonal methods.</li>\r\n<li>May be used as a temporary or supplemental method, but not considered <strong>ideal</strong> in terms of efficacy and compliance.</li>\r\n</ul>\r\n<p><strong>Combined OCP (Option B):</strong></p>\r\n<ul>\r\n<li><strong>Contains estrogen</strong>, which can <strong>reduce breast milk production</strong> and is therefore <strong>not recommended during early lactation</strong>.</li>\r\n<li>Also associated with <strong>increased thromboembolic risk</strong> in the postpartum period, particularly within the first 6 weeks.</li>\r\n</ul>\r\n<p><strong>Lactational amenorrhoea (Option C):</strong></p>\r\n<ul>\r\n<li>Can be an <strong>effective natural contraceptive</strong> method <strong>only under specific conditions</strong>:\r\n<ul>\r\n<li>Exclusive breastfeeding</li>\r\n<li>Infant &lt;6 months</li>\r\n<li>Amenorrhoea (no return of menses)</li>\r\n</ul>\r\n</li>\r\n</ul>",
      "correct_choice_id": 264,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 28,
      "choices": [
        {
          "id": 271,
          "text": "<p><span style=\"font-size:12.0pt;\">OCP</span></p>"
        },
        {
          "id": 272,
          "text": "<p><span style=\"font-size:12.0pt;\">Condom</span></p>"
        },
        {
          "id": 273,
          "text": "<p><span style=\"font-size:12.0pt;\">IUCD</span></p>"
        },
        {
          "id": 274,
          "text": "<p><span style=\"font-size:12.0pt;\">Mirena</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 24-year-old woman with well-controlled epilepsy on carbamazepine presents to the clinic for contraceptive counseling. She prefers a reliable, long-term method. Which of the following contraceptive methods is least appropriate in her case?</span></p>",
      "unique_key": "DT1191153",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191153,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This is the <strong>least appropriate</strong> choice in a woman with epilepsy who is taking <strong>carbamazepine</strong>, which is a <strong>hepatic enzyme inducer</strong> (induces cytochrome P450 enzymes).</p>\r\n<ul>\r\n<li>Combined oral contraceptives (COCs) are metabolized by the liver, and enzyme-inducing drugs like <strong>carbamazepine, phenytoin, phenobarbital, rifampicin</strong> reduce their effectiveness by <strong>accelerating estrogen and progestin metabolism</strong>.</li>\r\n<li>This results in <strong>increased risk of contraceptive failure and unintended pregnancy</strong>.</li>\r\n<li>Higher-dose estrogen pills or <strong>alternative methods</strong> (e.g., non-hormonal or long-acting reversible contraceptives) are recommended.</li>\r\n</ul>\r\n<h3><strong>Explanation of Incorrect Options:</strong></h3>\r\n<p><strong>Condom (Option B):</strong></p>\r\n<ul>\r\n<li>Safe and non-hormonal</li>\r\n<li><strong>No interaction</strong> with antiepileptic drugs (AEDs)</li>\r\n<li>While less effective than some long-acting methods, it is <strong>appropriate and safe</strong> in this context</li>\r\n</ul>\r\n<p><strong>IUCD (Option C):</strong></p>\r\n<ul>\r\n<li>Copper IUCD is <strong>non-hormonal</strong>, highly effective, long-acting, and <strong>not affected by enzyme inducers</strong></li>\r\n<li>Very suitable for women on AEDs</li>\r\n</ul>\r\n<p><strong>Mirena (LNG-IUS) (Option D):</strong></p>\r\n<ul>\r\n<li>Releases <strong>levonorgestrel locally</strong>, with <strong>minimal systemic absorption</strong></li>\r\n<li>Effectiveness is <strong>not significantly affected by enzyme-inducing AEDs</strong>, making it a safe and long-term option</li>\r\n</ul>",
      "correct_choice_id": 271,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 29,
      "choices": [
        {
          "id": 281,
          "text": "<p><span style=\"font-size:12.0pt;\">Length of tube <4 cms</span></p>"
        },
        {
          "id": 282,
          "text": "<p><span style=\"font-size:12.0pt;\">Patients over 30 years of age</span></p>"
        },
        {
          "id": 283,
          "text": "<p><span style=\"font-size:12.0pt;\">Pelvic tuberculosis</span></p>"
        },
        {
          "id": 284,
          "text": "<p><span style=\"font-size:12.0pt;\">Reversal done after 5 years of sterilization</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The following are the contraindications of tubal reconstructive surgery except:</span></p>",
      "unique_key": "DT1191154",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191154,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Patients over 30 years of age </strong>&nbsp;is <strong>not</strong> a contraindication to tubal reconstructive surgery.</p>\r\n<ul>\r\n<li>While <strong>advancing maternal age</strong> does <strong>reduce overall fertility</strong>, being <strong>over 30 years</strong> alone is <strong>not a contraindication</strong>.</li>\r\n<li>Many women in their 30s still have good ovarian reserve and are eligible for reversal surgery, especially if other conditions are favorable (e.g., adequate tubal length and no pelvic pathology).</li>\r\n</ul>\r\n<h3><strong>Explanation of the Incorrect Options </strong></h3>\r\n<p><strong>Length of tube &lt;4 cm (Option A):</strong></p>\r\n<ul>\r\n<li>After sterilization, <strong>residual tubal length</strong> is critical.</li>\r\n<li>A tube shorter than 4 cm is generally <strong>unsuitable for successful anastomosis</strong>, leading to poor outcomes.</li>\r\n</ul>\r\n<p><strong>Pelvic tuberculosis (Option C):</strong></p>\r\n<ul>\r\n<li>TB can cause <strong>extensive tubal, endometrial, and pelvic damage</strong>.</li>\r\n<li>Reconstructive surgery in such cases is <strong>contraindicated</strong> due to high failure rates, distorted anatomy, and increased risk of ectopic pregnancy.</li>\r\n</ul>\r\n<p><strong>Reversal done after 5 years of sterilization (Option D):</strong></p>\r\n<ul>\r\n<li>The longer the interval between sterilization and reversal, the <strong>worse the success rates</strong>.</li>\r\n<li>This is due to progressive fibrosis and shortening of tubal segments over time.</li>\r\n<li>Reversal after &gt;5 years is considered <strong>relatively contraindicated</strong>, especially if other adverse factors are present.</li>\r\n</ul>",
      "correct_choice_id": 282,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 30,
      "choices": [
        {
          "id": 291,
          "text": "<p><span style=\"font-size:12.0pt;\">Norplant</span></p>"
        },
        {
          "id": 292,
          "text": "<p><span style=\"font-size:12.0pt;\">Implanon</span></p>"
        },
        {
          "id": 293,
          "text": "<p><span style=\"font-size:12.0pt;\">Jadelle</span></p>"
        },
        {
          "id": 294,
          "text": "<p><span style=\"font-size:12.0pt;\">Mesigyna</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All of the following are contraceptive implants except:</span></p>",
      "unique_key": "DT1191155",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191155,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Mesigyna</strong> is a <strong>monthly injectable contraceptive</strong> containing <strong>norethisterone enanthate</strong> (a progestin) and <strong>estradiol valerate</strong> (an estrogen).</p>\r\n<p>It is given <strong>intramuscularly every month</strong> and acts by <strong>inhibiting ovulation</strong> and altering cervical mucus.</p>\r\n<p>It falls under the category of <strong>combined injectable contraceptives (CICs)</strong>.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904035398bc-8052-4992-a9d9-9693a9fa826a.png\"><p><strong>Explanation of the Other Options:</strong></p>\r\n<p><strong>Norplant (Option A):</strong></p>\r\n<ul>\r\n<li>One of the earliest contraceptive implants, containing <strong>levonorgestrel</strong> in <strong>six small silastic capsules</strong>.</li>\r\n<li>Provides contraception for <strong>up to 5 years</strong>.</li>\r\n<li>Now largely phased out in favor of newer implants.</li>\r\n</ul>\r\n<p><strong>Implanon (Option B):</strong></p>\r\n<ul>\r\n<li>A <strong>single-rod</strong> implant containing <strong>etonogestrel</strong>.</li>\r\n<li>Inserted subdermally in the upper arm.</li>\r\n<li>Provides contraception for <strong>3 years</strong>.</li>\r\n</ul>\r\n<p><strong>Jadelle (Option C):</strong></p>\r\n<ul>\r\n<li>Contains <strong>two rods</strong> of <strong>levonorgestrel</strong>.</li>\r\n<li>Provides contraception for <strong>up to 5 years</strong>.</li>\r\n<li>A newer and improved version compared to Norplant.</li>\r\n</ul>",
      "correct_choice_id": 294,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31,
      "choices": [
        {
          "id": 301,
          "text": "<p><span style=\"font-size:12.0pt;\">Falope ring</span></p>"
        },
        {
          "id": 302,
          "text": "<p><span style=\"font-size:12.0pt;\">Bipolar cautery</span></p>"
        },
        {
          "id": 303,
          "text": "<p><span style=\"font-size:12.0pt;\">Unipolar cauterisation</span></p>"
        },
        {
          "id": 304,
          "text": "<p><span style=\"font-size:12.0pt;\">Hulka clip</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The Least failure in sterilization occurs with:</span></p>",
      "unique_key": "DT1191156",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191156,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Unipolar cauterisation </strong>has the <strong>lowest failure rate</strong> among laparoscopic sterilization techniques.</p>\r\n<ul>\r\n<li>It involves applying <strong>unipolar electrocoagulation</strong> to the fallopian tubes, leading to <strong>deep thermal damage</strong> and <strong>complete tubal occlusion</strong>.</li>\r\n<li>Due to the <strong>extent of tubal destruction</strong>, chances of recanalization (and thus failure) are <strong>minimal</strong>.</li>\r\n<li>Reported failure rate: <strong>&lt;1 per 1,000 procedures</strong> (0.1%)</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904db16553b-0c30-4a16-8045-4d4ba8b4496c.png\"><p><strong>Explanation of the Incorrect Options:</strong></p>\r\n<p><strong>Falope ring (Option A):</strong></p>\r\n<ul>\r\n<li>Mechanical method using a silastic band to compress a loop of the tube</li>\r\n<li><strong>Failure rate</strong>: ~1-2 per 100 procedures (1-2%)</li>\r\n<li>Safer but less effective than cautery-based methods</li>\r\n<li>Moderate chance of spontaneous tubal recanalization</li>\r\n</ul>\r\n<p><strong>Bipolar cautery (Option B):</strong></p>\r\n<ul>\r\n<li>Uses electric current between two poles of the instrument</li>\r\n<li><strong>Less tissue spread</strong> compared to unipolar but also <strong>slightly higher failure rate</strong></li>\r\n<li>Failure rate: ~0.7-1%</li>\r\n</ul>\r\n<p><strong>Hulka clip (Option D):</strong></p>\r\n<ul>\r\n<li>Mechanical method using a plastic and metal clip</li>\r\n<li><strong>Failure rate</strong>: 2-3%</li>\r\n<li>Least tissue destruction &rarr; better for reversal, but <strong>more failures</strong></li>\r\n</ul>",
      "correct_choice_id": 303,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 32,
      "choices": [
        {
          "id": 311,
          "text": "<p><span style=\"font-size:12.0pt;\">IUCD</span></p>"
        },
        {
          "id": 312,
          "text": "<p><span style=\"font-size:12.0pt;\">DMPA</span></p>"
        },
        {
          "id": 313,
          "text": "<p><span style=\"font-size:12.0pt;\">POPs</span></p>"
        },
        {
          "id": 314,
          "text": "<p><span style=\"font-size:12.0pt;\">Implanon</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All of the following are long-acting reversible contraceptive methods except:</span></p>",
      "unique_key": "DT1191157",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191157,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Long-Acting Reversible Contraception</strong> is a contraceptive method that:</p>\r\n<ul>\r\n<li>Provide <strong>extended protection</strong> against pregnancy (from <strong>months to years</strong>)</li>\r\n<li>Are <strong>highly effective</strong> (&gt;99%)</li>\r\n<li>Require <strong>minimal user compliance</strong> after initiation</li>\r\n<li>Are <strong>reversible</strong>, with return of fertility soon after discontinuation</li>\r\n</ul>\r\n<p><strong>Progestin-only pills (POPs)</strong>, also known as <strong>mini-pills</strong>, do not fall under the LARC category because:</p>\r\n<ul>\r\n<li>They must be <strong>taken daily</strong> at the <strong>same time each day</strong></li>\r\n<li>Even a delay of more than <strong>3 hours</strong> in taking the pill can reduce efficacy</li>\r\n<li>Their effectiveness is <strong>user-dependent</strong>, unlike LARCs which are provider-dependent</li>\r\n<li>They have <strong>higher failure rates</strong> compared to implants, IUCDs, and injectables</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20240904386d9ec0-6a2c-4c5a-b2d7-b0eb3ede87e5.png\">",
      "correct_choice_id": 313,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}